06/24/22 9:09 AMNYSE, Nasdaq : RDY, ETON acquisitionDr. Reddy';s Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton PharmaReddy’ s Laboratories Ltd. today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based- Eton Pharmaceuticals, Inc.. The portfolio includes the Biorphen ® Injection and Rezipres ® Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved...RHEA-AIneutral
06/24/22 7:30 AMNasdaq : ETON low floatEton Pharmaceuticals Announces Sale of Hospital ProductsEton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseases Eton’s royalty portfolio is now eligible to receive up to $70 million inRHEA-AIvery positive
05/12/22 4:02 PMNasdaq : ETON earningslow floatEton Pharmaceuticals Reports First Quarter 2022 Financial ResultsEton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022. “We are proud toRHEA-AIvery positive
05/03/22 4:02 PMNasdaq : ETON conferencesearningslow floatEton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12,RHEA-AIneutral
04/11/22 4:01 PMNasdaq : ETON managementlow floatEton Pharmaceuticals Appoints James Gruber as Chief Financial OfficerEton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effectiveRHEA-AIpositive
04/11/22 7:30 AMNasdaq : ETON fda approvallow floatEton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride InjectionEton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug AdministrationRHEA-AIpositive
03/16/22 4:02 PMNasdaq : ETON earningslow floatEton Pharmaceuticals Reports Fourth Quarter 2021 Financial ResultsEton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments forRHEA-AIneutral
03/14/22 7:00 AMNasdaq : ETON low floatEton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection. Rezipres (4.7 mg/mL) is a ready-to-use 1 formulation of injectableRHEA-AIvery positive
03/08/22 8:00 AMNasdaq : ETON conferencesearningslow floatEton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on Wednesday, MarchRHEA-AIneutral
12/20/21 7:30 AMNasdaq : ETON low floatEton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)EtonRHEA-AIpositive